AOD-9604: what the human research actually shows
AOD-9604 is one of the few peptides that actually got a proper Phase 2b trial in humans. The trial failed. Most of the internet pretends that sentence doesn’t exist, and it is the whole story.
Why I looked into this
AOD-9604 is marketed across biohacker sites as a clean, targeted fat-loss peptide derived from growth hormone but without the growth hormone side effects. The pitch is almost always framed as if the human evidence is supportive. That framing is what made me go pull the actual trial papers.
What I found is not a mystery. The Phase 2b obesity trial was run, it was published, and it did not show the effect the product was being developed to demonstrate. The gap between what the trials actually showed and what the current marketing implies is the reason this monograph exists.
What AOD-9604 actually is
AOD-9604, sometimes written as AOD9604 or Advanced Obesity Drug 9604, is a synthetic 16-amino-acid peptide. It corresponds to the C-terminal end of human growth hormone, specifically residues 177 to 191 of the hGH molecule, with a tyrosine added at the N-terminus to stabilize the fragment. It was designed to isolate what researchers hypothesized was the lipolytic portion of growth hormone without triggering growth hormone’s broader metabolic and anabolic effects.
The compound was developed by Metabolic Pharmaceuticals, a public Australian biotech, through the late 1990s and 2000s. Pre-clinical work suggested it could mobilize fat without raising insulin-like growth factor 1 or producing the glucose-handling problems associated with full growth hormone. That hypothesis was the entire commercial thesis. Then the human trials actually happened.
What the human research shows
Do published human trials exist?
Yes. And unlike many peptides on this site, the human trials include a proper Phase 2b obesity study, not just small case series.
That is why AOD-9604 is an unusual case. The honest reader who actually goes and reads the human literature will walk away more skeptical, not less. The human evidence is not the reason to be excited about this compound. It is the reason to be cautious.
What evidence actually exists?
The most-cited human studies are:
- Heffernan et al., European Journal of Endocrinology, 2001: an early Phase 1 pharmacokinetic and acute metabolic study in healthy adults and obese subjects, showing the fragment was absorbed and produced short-term changes in fat oxidation markers without raising IGF-1.
- Ng et al., Obesity, 2008: a short-term study in obese adults, reporting small effects on lipolysis and fat oxidation markers over a limited observation window.
- Metabolic Pharmaceuticals Phase 2b obesity trial: a multi-week randomized placebo-controlled study in obese adults, evaluating weight loss versus placebo. The trial did not meet its primary endpoint of clinically significant weight loss versus placebo. Development for the obesity indication was then discontinued by the sponsor.
- Separate GRAS (Generally Recognized As Safe) dossier: submitted in some markets for use as a nutritional ingredient, not as a drug approval and not as an efficacy finding.
What the research does not show
The research does NOT show:
- That AOD-9604 produces clinically significant weight loss in obese adults. The Phase 2b trial, designed specifically to answer that question, did not find it.
- That it is an FDA-approved obesity drug, or was ever close to becoming one. Development was abandoned after the Phase 2b failed.
- That GRAS status is evidence of fat-loss efficacy. GRAS is a food-ingredient safety designation, not a drug efficacy finding. Marketing that blurs the two is misleading.
- That it produces body-composition changes at a level a person would notice in a realistic timeframe. Short-term lipolysis markers are not the same thing as actual fat loss on a scale or a DEXA.
- Any benefit for joint healing, cartilage repair, or athletic recovery in humans. Those claims are sometimes attached to AOD-9604 online and have no Phase 2 human trial backing them.
The claim you will see most often online is that AOD-9604 is a studied, human-trialed fat loss compound. The first half of that sentence is true. The second half is the part the Phase 2b trial directly contradicted.
Known safety signals in humans
On the safety side, the published human trials generally described AOD-9604 as well tolerated across short-term dosing, without the IGF-1 elevation or insulin-sensitivity problems associated with full growth hormone. No signal of acute severe adverse events was reported in the Phase 1 and Phase 2 data that made it into print.
That is a narrower safety story than it sounds. The trials were short. The Phase 2b obesity program was abandoned after the efficacy failure, so there is no long-term human safety follow-up in a large cohort. There is no post-market pharmacovigilance system capturing real-world adverse events because this was never approved as a drug. Absence of published safety signals is not the same as confirmed long-term safety.
FDA and legal status in the US
There is no active FDA pathway for AOD-9604 in the United States. It is not approved, it is not in the current 503A compounding framework, and it is not on the July 2026 Pharmacy Compounding Advisory Committee agenda. The regulatory record in the US is essentially quiet because the sponsor walked away from the obesity indication after the Phase 2b efficacy failure.
GRAS status as a nutritional ingredient, in markets where that status was obtained, is a food-safety designation only. It is not an FDA drug approval, it is not a finding of efficacy for weight loss, and it does not make AOD-9604 a legally marketed weight-loss product in the US.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for AOD-9604 specifically
The specific source-safety problem with AOD-9604 is that it is a 16-amino-acid fragment that most research-use-only sellers are not equipped to verify by identity. Peptide fragments of this length are commonly mis-synthesized, truncated, or substituted with cheaper related fragments, and the buyer has no way to tell without third-party mass spectrometry.
Because AOD-9604 was never an approved drug, there is no USP monograph, no enforced identity standard, and no independent reference product to compare a sample against. What a vial is labeled as and what it actually contains are two different questions, and the honest answer for most of the current market is that nobody outside the seller is answering the second question.
Cost reality
Expect a wide range for material labeled as AOD-9604 on the research-use-only market. A licensed 503A compounding pharmacy willing to compound it under physician supervision would cost meaningfully more, with the clinical oversight layered in.
Cost is a poor quality signal here. Cheaper material is usually a worse identity bet; more expensive material is not guaranteed to be authentic either. The only reliable quality signal is independent identity and purity testing by a lab that is not owned by the seller, and most buyers never see that report.
Questions worth asking any source
- Are you a licensed 503A compounding pharmacy with a verifiable US state license?
- Do you provide a certificate of analysis from an independent third-party lab, not in-house testing only?
- Do you require a valid prescription from a licensed clinician?
- Do you have a physical US address and a phone number I can verify by calling?
- Which specific 16-amino-acid sequence is in this vial, and what analytical method (mass spec, HPLC) did you use to confirm both identity and purity?
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used AOD-9604. If I were looking at fat loss today, AOD-9604 would not be on my list, and the reason is specifically because the human data exists and is the unflattering part. For most peptides on this site, I can say “the evidence is weak because nobody ran the trial.” For AOD-9604, someone ran the trial, it was properly designed, and it did not show the effect the product was being developed to show.
Something about the AOD-9604 discourse bothers me more than most. The internet writeups of this compound talk about it as if it is a studied, validated fat-loss peptide, and they skip the part where the sponsor looked at the Phase 2b data and walked away. That sponsor had every incentive to keep going if the data had looked good. They stopped. That is a real piece of information about the compound.
The category where I could be talked into a narrower, more modest reading is the short-term lipolysis marker work. Something happens in fat metabolism when this fragment is administered to humans. But short-term biochemical markers of fat oxidation are not the same claim as “this will meaningfully change your body composition,” and every Phase 2b ever run is designed exactly to tell those two claims apart. The Phase 2b told them apart.
For someone who is curious, I would read the Heffernan 2001 paper and the Phase 2b obesity trial record yourself, not the writeups. For someone considering use, the FDA-approved GLP-1 and dual-agonist drugs have human outcome data at a scale AOD-9604 will never have, and that is the honest comparison a clinician is going to draw. For someone who has already decided to try it, the source-safety framework matters more here than for most compounds on this site.
Questions to ask your doctor
If you are considering AOD-9604, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- I have been reading about AOD-9604 and the published human trial record, including the Phase 2b obesity trial that did not meet its primary endpoint. Given that history, is there a clinical reason a compound like this would be worth discussing in my specific situation?
- If I were to consider this compound, what baseline metabolic and body-composition measurements would you want to see first, and what would you want to re-check later?
- Given that the sponsor abandoned development after the Phase 2b efficacy failure, how would you weigh that in your clinical judgment compared to what is currently marketed online about this compound?
- If weight loss is the outcome I am actually after, how would you compare the human evidence base for AOD-9604 to the FDA-approved GLP-1 and dual-agonist options?
- If I developed unusual symptoms while using a growth-hormone-derived fragment (glucose changes, unexpected metabolic shifts, fatigue), what should I do and who should I contact first?
- Is there a conventional or FDA-approved option that addresses whatever outcome I am hoping AOD-9604 would produce, that we should try or rule out first?
What to do next
Read the primary research
Start with Heffernan 2001 in the European Journal of Endocrinology and the Phase 2b obesity trial record. Read the primary literature, not the writeups.
Open the primer →Compare against the approved options
If weight loss is the goal, the honest comparator is the human outcome data for FDA-approved GLP-1 and dual-agonist drugs. Bring the visit-prep packet to that conversation.
Get the packet →Source-safety first, always
Identity verification is genuinely unreliable for 16-amino-acid fragments on the research-use-only market. The 503A checklist matters more here, not less.
Open the checklist →Sources
- Heffernan M et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology / related hGH fragment pharmacology series. PubMed search.
- Ng FM et al. “Studies on the anti-obesity activity of a beta cell tropic fragment of human growth hormone (AOD9604) in obese humans.” Published human metabolic work on AOD-9604 in obese adults, 2000s. PubMed search.
- Metabolic Pharmaceuticals Ltd. ASX disclosures and regulatory filings, Phase 2b obesity trial results, development discontinuation notice. Archived Australian Securities Exchange announcements, mid-to-late 2000s.
- US FDA. Generally Recognized As Safe (GRAS) framework overview. “GRAS is a designation of food-ingredient safety status and is distinct from FDA drug approval or any finding of drug efficacy.” FDA GRAS overview.
- Sinha DK, Mohan H. “Role of growth hormone fragment (AOD9604) in adipose tissue metabolism: review of the human evidence.” Review article summarizing the Metabolic Pharmaceuticals human development program.
The citation floor here is the published human trial record. Every claim in this monograph is tied to that record or to the explicit absence of a record where one would be expected.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Semaglutide
The honest comparator. An FDA-approved weight-loss drug with multiple Phase 3 RCTs and outcome data at a scale AOD-9604 never reached.
Tirzepatide
The other serious comparator for anyone thinking about a fat-loss peptide. FDA approved, with a Phase 3 outcome base that AOD-9604 was designed to compete with and did not.
Ipamorelin
The other growth-hormone-adjacent peptide that gets pitched for body composition. No Phase 2 human trial record, which is a different kind of evidence gap than AOD-9604’s.